Hepatitis C Background and Patent Search

1
Hepatitis CBackground and Patent Search

• Denis Rubin
• BME 501

2
Review

• Viral, blood-borne disease caused by hepatitis C
  virus (HCV)
• May lead to lead to cirrhosis and liver cancer
• Affects millions of people worldwide
• RNA virus
• RNA replication ?1 mutation per 10,000
  nucleotides
• Multiple strains HCV 1a,1b,2,3,4,5,6,7,8,9,etc.
• Strains of HCV genome vary by as much as 33
• Difficult to identify, detect, target

3
Treatment alpha Interferon

• Interferons
• cytokines that are naturally produced by white
  blood cells to help fight infections and inhibit
  abnormal tissue growth in the body.
• alpha Interferon Effects
• makes healthy cells less susceptible to the
  effects of the virus
• prevents the virus from infecting healthy cells
• Exact mechanism of action unclear
• Cytotoxic
• Cytostatic
• Antiproliferative antiviral
• Immunomodulary

http//www.aidsinfonyc.org/tag/coinf/hcv2004/index
.html M.D. Weltman and N.J. Talley, Chronic
hepatitis C infection a review and update on
treatment strategies, ADF Health 2003 4 27-33
4
Treatment Pegylated alpha Interferon

• PEG (polyethylene glycol) alpha Interferon
• Add a covalently bound polyethylene glycol
• Higher molecular weight increases serum half-life
• Bigger molecule stays in the body longer)
• Prevents interferon breakdown
• Two forms of PEG-alpha interferon approved by
  FDA
• PEG alpha-2a (Pegasys)
• 40kd branched PEG
• Increases half-life from 5.1 to 50-140 hours
• PEG alpha-2b (Peg-Intron)
• 12kd linear PEG
• Increases half-life from 3.6 to 40 hours

http//www.hepatitisinnovations.com/readytolearn/g
etting_treated/approved/alpha_interferons.jsp http
//www.aidsinfonyc.org/tag/coinf/hcv2004/index.htm
l
5
Treatment - Ribavirin

• Ribavirin
• Ineffective on its own
• Used in conjunction with alpha Interferon
• More effective than monotherapy
• Prevents virus replication, reducing viral load
• Reduces HCV RNA level to undetectable in 30-40
  of patients

http//www.hepatitisinnovations.com/readytolearn/g
etting_treated/approved/alpha_interferons.jsp
6
Treatment Issues

• Ineffectiveness
• Targets particular genotypes of HCV
• Helps only 30-40 of patients
• Developed resistance
• Side effects
• Fatigue, muscle aches, weight loss, nausea,
  depression, irritability, headache and insomnia
• Few cases of loss of vision and hearing
• Birth defects
• Reduction in blood cells
• Mental health problems major depression and
  anxiety
• 24 or 48 weeks, depending on the HCV genotype

http//hepatitisc.org.au/resources/documents/52-1.
pdf http//www.aidsinfonyc.org/tag/coinf/hcv2004/i
ndex.html
7
Proposed Solution

• Approach from a different perspective
• DNA matter-wave duality
• P.P. Gariaev et al has shown that DNA emits light
  which is gene- and sign-modulated by amplitude,
  phase, frequency and polarization
• the genome is also likely to be a radio wave
  emitter converting a wide spectrum of coherent
  sign-polarized radio bands
• Dzang Kangeng Yu.V., Patent N1828665. A method of
  changing biological objects hereditary signs and
  a device for biological information directed
  transfer. Application N3434801, invention
  priority as of 30.12.1981, registered 13.10.1992.

P.P.Gariaev, G.G.Tertishny, A.M. Iarochenko,
V.V.Maximenko, E.A.Leonova, 2002, The
spectroscopy of biophotons in non-local genetic
regulation. Peter P.Gariaev, George G.
Tertishny, Katherine A. Leonova., 2002, The Wave,
Probabilistic and Linguistic Representations of
Cancer and HIV. Journal of Non-Locality and
Remote Mental Interactions Vol. I, ?.2